Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis

British Journal of Dermatology

Volumn 174, Issue 1, 2016, Pages 201-203

  Politiek, K ^a   Van Der Schaft, J ^b   Coenraads, P J ^a   De Bruin Weller, M S ^b   Schuttelaar, M L A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PREDNISOLONE; DERMATOLOGICAL AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; ATOPIC DERMATITIS; COHORT ANALYSIS; DRUG DOSE INCREASE; DRUG SURVIVAL; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ICD-10; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DERMATITIS, ATOPIC; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; TIME FACTOR; TREATMENT OUTCOME;

DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84955748858     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13961     Document Type: Article

References (11)

1. Schram ME, Roekevisch E, Leeflang MM, et al,. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128: 353-9.
2. Lyakhovitsky A, Barzilai A, Heyman R, et al,. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 2010; 24: 43-9.
3. El-Khalawany MA, Hassan H, Shaaban D, et al,. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr 2013; 172: 351-6.
4. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ,. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007; 156: 346-51.
5. Goujon C, Berard F, Dahel K, et al,. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006; 16: 155-8.
6. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Available at http://apps.who.int/classifications/icd10/browse/2015/en (last accessed 16 June 2015).
7. Williams HC, Burney PG, Pembroke AC, Hay RJ,. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. Br J Dermatol 1996; 135: 12-17.
8. Hijnen DJ, ten Berge O, Timmer-de Mik L, et al,. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 2007; 21: 85-9.
9. Christoffers WA, Politiek K, Coenraads PJ, et al,. Drug survival of cyclosporine in the treatment of hand eczema: a multicentre, daily use study. J Eur Acad Dermatol Venereol 2015; 30: 63-66.
10. van der Schaft J, Politiek K, van den Reek JM, et al,. Drug survival for cyclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 2015; 172: 1621-7.
11. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.